Why the study?
Increased maternal body mass index is associated with adverse clinical outcomes, and the role of visfatin in pregnancy-related disorders linked to obesity warrants review.
Can the adipokine visfatin serve as a novel marker of pregnancy-related disorders in women with obesity?
Can the adipokine visfatin serve as a novel marker of pregnancy-related disorders in women with obesity?
Visfatin may have predictive and prognostic value as a biomarker for pregnancy-related disorders in women with obesity.
Answers are grounded in this paper and cite their sources.
May support visfatin evaluation in obese pregnancies; leaves open clinical adoption pending prospective validation.
Overweight and obesity have become a dangerous disease requiring multiple interventions, treatment and preventions. In women of reproductive age, obesity is one of the most common medical conditions. Among others, obese state is characterized by low-grade systemic inflammation and enhanced oxidative stress. Increased maternal body mass index might amplify inflammation and reactive oxygen species production, which is associated with unfavourable clinical outcomes that affect both mother and child. Intrauterine growth retardation, preeclampsia, or gestational diabetes mellitus are examples of the hampered maternal and foetoplacental unit interactions. Visfatin is the obesity-related adipokine produced mainly by the visceral adipose tissue. Visfatin affects glucose homeostasis, as well as the regulation of genes related to oxidative stress and inflammatory response. Here, we review visfatin interactions in pregnancy-related disorders linked to obesity. We highlight the possible predictive and prognostic value of visfatin in diagnostic strategies on gravidas with obesity.
No takes yet. Share an insight, caveat, or question.
Wnuk et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: